Strong results, clinical progress, capital raises and bullish analyst calls boosted investor confidence.

Amylyx surges after avexitide cuts hypoglycemic events 55% in phase III LUCIDITY study, paving the way for an FDA filing by end-2026 in PBH.

Amylyx Pharmaceuticals (NasdaqGS: AMLX) reported overwhelmingly positive topline Phase 3 results for avexitide in post-bariatric hypoglycemia, with the trial meeting its primary and all secondary endpoints. The data support a planned NDA filing for avexitide in PBH, a condition that currently has no FDA-approved therapies. Alongside the clinical update, Amylyx completed a substantial follow-on public equity offering to fund pre-commercial work and broader R&D efforts. For more context on...

Investors responded to clinical progress, improving commercial performance and new growth opportunities.

Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) soared to a new three-year high on Tuesday after its treatment candidate for post-bariatric hypoglycemia (PBH) reported strong results in phase 3 clinical studies, paving the way for its looming commercialization. In intra-day trading, the stock surged to a record of $35.39 before trimming a few cents to end the session […]

GLP-1 drugs aren't just for weight loss.

The capital raise comes as Amylyx prepares to move from clinical success toward potential commercialization, following the positive trial data for avexitide announced earlier today.

FEATURE Stocks dropped Tuesday, dragged down by pressure on artificial-intelligence infrastructure companies and heightened tensions in the Middle East. Optical network provider Coherent sank 13%, making it the worst-performing stock in the The stock surged 7.

Amylyx stock skyrocketed Tuesday after its GLP-1 drug reduced hypoglycemia in patients who've undergone bariatric surgery.

Amylyx shares rally on promising avexitide, a GLP-1 receptor antagonist, data. But should you load up on AMLX stock on strength today? Let’s find out!

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S

Amylyx Pharmaceuticals shares rose 64% Tuesday after the company announced that its experimental treatment for a condition called post-bariatric hypoglycemia, or PBH, reduced the rate of significant blood-sugar crashes by 55% compared with a placebo in a late-stage trial. PBH, which sets in after a person undergoes bariatric surgery for weight loss, causes severe blood sugar drops after eating and affects roughly 160,000 in the U.S. There are currently no treatments approved by the Food and Drug Administration. Cambridge, Mass.-based Amylyx plans to submit the drug to the FDA for approval by the end of 2026, and is aiming for a potential commercial launch next year.

Patients on avexitide experienced 55% fewer severe hypoglycemic events than those on a placebo in the late-stage study

Amylyx said the company said it will release top-line results from its late-stage trial of blood sugar drug avexitide on Tuesday.

Amylyx Pharmaceuticals stock has delivered a 170.4% return over the past year, yet its valuation checks and market multiples suggest the shares are not obviously cheap. After this strong run, investors are facing a stock that screens as expensive on several metrics, despite the momentum. Amylyx Pharmaceuticals is up 170.4% over the last year, which puts extra focus on whether the current share price still lines up with the company’s fundamentals. Progress with avexitide, including the...

Amylyx Pharmaceuticals (AMLX) stock is in focus after the company reported a Q2 2026 net loss of US$43.42 million and a basic loss per share of US$0.39 from continuing operations. See our latest analysis for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals shares have pulled back in the very short term, with a 1-day share price return of 3.78% and 7-day share price return of 5.21%. These moves sit against a much stronger 30-day share price return of 21.65%, 90-day share price return of 62.82%,...

Amylyx Pharmaceuticals reported second-quarter 2026 results showing a net loss of US$43.42 million and basic loss per share from continuing operations of US$0.39, alongside confirmation that it is progressing toward a pivotal Phase III data readout for avexitide in post-bariatric hypoglycemia. Although losses widened over the first half of 2026, the improvement in loss per share and continued preparation for potential avexitide commercialization highlight how Amylyx is spreading its R&D and...

LUCIDITY data readout expected late August or early September.

Vertex Pharmaceuticals, Amylyx Pharmaceuticals, Praxis Precision Medicines and BridgeBio Pharma face major 2026 catalysts, from FDA decisions to late-stage readouts.

Here is how Editas Medicine (EDIT) and Amylyx Pharmaceuticals, Inc. (AMLX) have performed compared to their sector so far this year.

Amylyx Pharmaceuticals Inc (AMLX) reports strong progress on its Phase 3 trial and commercial preparations, with top-line data expected in late August or early September 2026.

Amylyx Pharmaceuticals (NASDAQ:AMLX) said its pivotal Phase III LUCIDITY trial of avexitide in post-bariatric hypoglycemia, or PBH, has completed final patient visits, with top-line data expected in late August or early September. The company remains blinded to the data and said the trial database